Immunocore's bispecific lands speedy review with FDA, EMA; Low-profile gene therapy player grabs $30M
UK TCR-focused biotech Immunocore announced that it scored a priority review with the FDA for lead drug tebentafusp.
The bispecific already …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
